In-Clinic and Home-Use Study of a New Blood Glucose Monitoring System

NCT ID: NCT00803777

Last Updated: 2016-02-29

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

147 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-12-31

Study Completion Date

2009-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the performance and acceptability of a new blood glucose meter.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intended Users of the Monitoring System

Subjects with type 1 diabetes and healthcare professionals (HCP) used a new blood glucose monitoring system (BGMS) with subject capillary blood. Any subject under age 18 was accompanied by a parent or guardian, who assisted subject if applicable.

Group Type EXPERIMENTAL

Investigational Blood Glucose Monitoring System

Intervention Type DEVICE

Subjects with diabetes used a new blood glucose monitoring system with capillary blood. Certain results were compared to a laboratory glucose method.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Investigational Blood Glucose Monitoring System

Subjects with diabetes used a new blood glucose monitoring system with capillary blood. Certain results were compared to a laboratory glucose method.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type 1 diabetes
* Age 4 to 24 years
* Routinely performs blood glucose testing at home, at least 2 times per day, for one month or more before enrollment
* Has used a handheld game system to play video games within a year of enrollment
* If above age 18, subject is able to speak, read, and understand English. If below age 18, subject's parent/guardian is able to speak, read, and understand English, and is able to provide appropriate supervision.
* Is willing to complete all study procedures, with appropriate parent/guardian supervision

Exclusion Criteria

* Hemophilia or any other bleeding disorder
* Taking prescription anticoagulants (such as Warfarin or heparin) or has clotting problems that may prolong bleeding. Taking Plavix or aspirin daily is not excluded
* Infection with a blood borne pathogen (e.g., HIV, hepatitis)
* Subject or parent/guardian is employee of competitive medical device company
* Cognitive disorder or other condition, which in the opinion of the investigator, would put the person at risk or seriously compromise the integrity of the study
Minimum Eligible Age

4 Years

Maximum Eligible Age

24 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ascensia Diabetes Care

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Javier Aisenberg, MD

Role: PRINCIPAL_INVESTIGATOR

Hackensack Meridian Health

Georgeanna Klingensmith, MD

Role: PRINCIPAL_INVESTIGATOR

Barbara Davis Center

Francine Kaufman, MD

Role: PRINCIPAL_INVESTIGATOR

Children's Hospital Los Angeles

Timothy Bailey, MD

Role: PRINCIPAL_INVESTIGATOR

AMCR Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

AMCR Institute

Escondido, California, United States

Site Status

Childrens Hospital Los Angeles

Los Angeles, California, United States

Site Status

Barbara Davis Center

Aurora, Colorado, United States

Site Status

Hackensack University Medical Center

Hackensack, New Jersey, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Parkes JL, Slatin SL, Pardo S, Ginsberg BH. A new consensus error grid to evaluate the clinical significance of inaccuracies in the measurement of blood glucose. Diabetes Care. 2000 Aug;23(8):1143-8. doi: 10.2337/diacare.23.8.1143.

Reference Type RESULT
PMID: 10937512 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CTD-2008-23

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Home Use Sensor Study
NCT02932514 UNKNOWN NA
Blood Glucose Testing and You
NCT01453413 COMPLETED NA
Accuracy of Freestyle Libre
NCT02734745 UNKNOWN NA